Literature DB >> 10370622

Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes' B2 rectal cancer after curative resection.

J T Liang1, Y M Cheng, K J Chang, C T Chien, H C Hsu.   

Abstract

BACKGROUND/AIMS: Recurrence of rectal cancer remains a major clinical problem. This study was conducted to evaluate the impact of K-ras and p53 mutations on the recurrence of rectal cancer.
METHODOLOGY: A total of 166 resected Dukes' B2 stage rectal carcinomas were collected between January 1990 and April 1994. The stored frozen tissues were retrieved for immunocytochemistry of p53 and genomic analysis of K-ras and p53 genes. The data of K-ras and p53 gene mutations were correlated with clinicopathological variables. The concordance of immunocytochemistry with genomic analysis in the survey of p53-mutations was examined. The follow-up data were analyzed by Kaplan-Meier estimator.
RESULTS: Sixty-nine patients (41.6%) developed recurrent tumor. A significantly higher recurrence rate (p = 0.0013) and shorter median recurrence time were noted in p53 mutated than non-mutated cancers. Mutations in K-ras gene do not significantly increase the risk of tumor recurrence (p = 0.1702). K-ras and p53 mutations are not associated with clinicopathological parameters (p > 0.05). Kappa statistic indicates highly significant reproducibility between immunocytochemistry and genomic analysis for p53 mutations (p < 0.0001).
CONCLUSIONS: Presence of p53 mutation significantly increases the recurrence rate and shortens the recurrence time of the resected rectal cancers. Pre-operative routine check for p53 mutations by immunocytochemistry may be beneficial in choosing the optimal surgical strategy for rectal cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10370622

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  7 in total

Review 1.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

2.  Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population.

Authors:  Jyh-Ming Liou; Ming-Shiang Wu; Chia-Tung Shun; Han-Mo Chiu; Mei-Jyh Chen; Chien-Chuan Chen; Hsiu-Po Wang; Jaw-Town Lin; Jin-Tung Liang
Journal:  Int J Colorectal Dis       Date:  2011-05-07       Impact factor: 2.571

3.  Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer-rarity of co-occurrence of mutations in APC, K-ras, and p53 genes.

Authors:  Jy-Ming Chiang; Yah-Huei Wu Chou; Shih-Chieh Ma; Jim-Ray Chen
Journal:  Virchows Arch       Date:  2004-09-24       Impact factor: 4.064

Review 4.  Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients.

Authors:  Kristen M Drescher; Poonam Sharma; Henry T Lynch
Journal:  Clin Dev Immunol       Date:  2010-06-10

Review 5.  Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.

Authors:  B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor
Journal:  Int J Colorectal Dis       Date:  2003-06-21       Impact factor: 2.571

6.  An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation.

Authors:  S Cascinu; F Graziano; V Catalano; M P Staccioli; M C Rossi; A M Baldelli; S Barni; A Brenna; S Secondino; P Muretto; G Catalano
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

7.  Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation.

Authors:  Jin-Tung Liang; Tzu-Chun Chen; John Huang; Yung-Ming Jeng; Jason Chia-Hsien Cheng
Journal:  Oncotarget       Date:  2017-10-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.